Citius Oncology (CTOR) said Friday that Dr. Reddy's Laboratories (RDY) agreed to a partial deferral without penalty of a milestone payment by Citius that was triggered upon the US Food and Drug Administration's approval of the Lymphir cancer therapy.
The milestone payment was due Sept. 9, Citius said in a filing with the US Securities and Exchange Commission.
The company said that except for the partial deferral of the milestone payment, its September 2021 asset purchase agreement with Dr. Reddy's remains in full force and effect.
CTOR shares were up 3.7% in recent Friday trading while RDY shares were climbing 0.4%.
Price: 80.51, Change: +0.25, Percent Change: +0.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。